IL6 and metabolic dysfunction-associated steatotic liver disease: It reduces key markers of liver damage (ALAT, AST, and GGT), inflammation (TNF-α and IL-6), and lipid metabolism dysfunction, making it a promising therapeutic candidate for managing MASLD and potentially IFALD, which, despite differing etiology, share some similarities in the pathomechanism.